Home Cart Sign in  
Chemical Structure| 313348-27-5 Chemical Structure| 313348-27-5

Structure of Regadenoson
CAS No.: 313348-27-5

Chemical Structure| 313348-27-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Regadenoson is a selective adenosine A2A receptor agonist with Ki value of 1.1nM for pig striatum A2A receptor, used as a novel pharmacologic stress agent under clinical development for myocardial perfusion imaging.

Synonyms: CVT-3146; Lexiscan

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Regadenoson

CAS No. :313348-27-5
Formula : C15H18N8O5
M.W : 390.35
SMILES Code : CNC(C1=CN(C2=NC(N)=C3C(N([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)C=N3)=N2)N=C1)=O
Synonyms :
CVT-3146; Lexiscan
MDL No. :MFCD09832544
InChI Key :LZPZPHGJDAGEJZ-AKAIJSEGSA-N
Pubchem ID :219024

Safety of Regadenoson

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Regadenoson

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02115308 Coronary Artery Disease PHASE4 COMPLETED 2018-03-23 Saint Luke's Health System, Ka... More >>nsas City, Missouri, 64111, United States Less <<
NCT00837369 Coronary Artery Disease|Myocar... More >>dial Perfusion Abnormalities Less << PHASE1 COMPLETED 2011-12-01 Mayo Clinic, Rochester, Minnes... More >>ota, 55905, United States|University of Nebraska Medicial Center, Omaha, Nebraska, 68105, United States Less <<
NCT00881218 Ischemic Heart Disease EARLY_PHASE1 COMPLETED 2025-12-11 Washington University School o... More >>f Medicine, St. Louis, Missouri, 63110, United States Less <<
NCT04604782 Myocardial Ischemia|Coronary A... More >>rtery Disease Less << PHASE1|PHASE2 RECRUITING 2025-12-26 Paris Public Hospitals System;... More >> Necker Hospital for Sick Children, Paris, 75015, France|Mitera Hospital, Athens, 15123, Greece|Bambino Gesu Children Hospital, Roma, 00165, Italy|Bristol Royal Hospital for Children, Bristol, BS28BJ, United Kingdom|King's College London, Rayne Institute, London, SE1 7EH, United Kingdom Less <<
NCT01840696 Coronary Artery Disease PHASE2 WITHDRAWN 2025-05-14 Emory University Hospital, Atl... More >>anta, Georgia, 30322, United States Less <<
NCT02220634 Pulmonary Hypertension TERMINATED 2017-05-25 National Jewish Health, Denver... More >>, Colorado, 80206, United States Less <<
NCT01779869 Ischemic Heart Disease PHASE4 COMPLETED 2025-06-15 Center for Clinical Imaging Re... More >>search at Washington University School of Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT01969916 Coronary Artery Disease COMPLETED 2025-06-18 University of Chicago Medical ... More >>Center, Chicago, Illinois, 60637, United States Less <<
NCT02697877 Coronary Artery Disease COMPLETED 2025-07-18 1740 W Taylor Street, 2nd Floo... More >>r, Cardiac Imaging, Chicago, Illinois, 60612, United States Less <<
NCT03103061 Cardiovascular Diseases|Corona... More >>ry Artery Disease Less << PHASE2 COMPLETED 2018-06-14 Medical University of South Ca... More >>rolina, Charleston, South Carolina, 29425, United States Less <<
NCT02130453 Ischemia PHASE4 COMPLETED 2024-06-28 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT03102125 Heart Transplant Failure and R... More >>ejection Less << PHASE4 RECRUITING 2024-12-02 UC San Diego, La Jolla, Califo... More >>rnia, 92037, United States Less <<
NCT01085201 Sickle Cell Disease PHASE1 COMPLETED 2025-03-13 Howard University Hospital, Wa... More >>shington, District of Columbia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Childrens Hospital Boston, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Washington University, St. Louis, Missouri, United States|Blood Center of Wisconsin, Milwaukee, Wisconsin, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.56mL

0.51mL

0.26mL

12.81mL

2.56mL

1.28mL

25.62mL

5.12mL

2.56mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories